

Title: Urothelial and Colorectal Cancer

Reference Number: RDF1365-23

Date of Response: 19/04/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I am researching the incidence and treatment of Urothelial and Colorectal Cancer. I would greatly appreciate if you could answer the following two questions.

- 1. How many urothelial cancer patients (renal pelvis, ureter and urethra, small cell bladder cancer) have been treated in the past 3 months with the following agents:*

<i>Agent</i>	<i>Royal Devon No. of Patients</i>
<i>Avelumab</i>	<i>≤5</i>
<i>Atezolizumab</i>	<i>≤5</i>
<i>Carboplatin with Gemcitabine</i>	<i>≤5</i>
<i>Carboplatin single or in any other combination</i>	<i>≤5</i>
<i>Cisplatin with Gemcitabine</i>	<i>≤5</i>
<i>Cisplatin single or in any other combination</i>	<i>≤5</i>
<i>Nivolumab</i>	<i>Nil</i>
<i>Pembrolizumab</i>	<i>Nil</i>
<i>Any other regimen including Paclitaxel</i>	<i>Nil</i>
<i>Any other chemotherapy regimen</i>	<i>≤5</i>
<i>Other active systemic anti-cancer therapy</i>	<i>Nil</i>
<i>Palliative care only</i>	<i>≤5</i>

Answer: Please see table above, representing the latest available data for 1st September 2022 to 30th November 2022.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

2. *How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:*

<i>Agent</i>	<i>Royal Devon No. of Patients</i>
<i>Aflibercept</i>	Nil
<i>Bevacizumab</i>	Nil
<i>Capecitabine</i>	22
<i>CAPIRI</i>	≤5
<i>CAPOX (XELOX)</i>	38
<i>Cetuximab in combination with FOLFIRI</i>	12
<i>Cetuximab in combination with FOLFOX</i>	Nil
<i>Cetuximab not in combination with FOLFIRI or FOLFOX</i>	≤5
<i>Irinotecan only</i>	≤5
<i>FOLFIRI</i>	Nil
<i>FOLFOX</i>	Nil
<i>Fluorouracil (5FU) only</i>	Nil
<i>Oxaliplatin only</i>	Nil
<i>Panitumumab in combination with FOLFIRI</i>	Nil
<i>Panitumumab in combination with FOLFOX</i>	Nil
<i>Panitumumab not in combination with FOLFIRI or FOLFOX</i>	Nil
<i>Pembrolizumab</i>	≤5
<i>Nivolumab</i>	≤5
<i>Raltitrexed</i>	Nil
<i>Ramucirumab</i>	Nil
<i>Regorafenib</i>	Nil
<i>Sorafenib</i>	Nil
<i>Other active systemic anti-cancer therapy</i>	76
<i>Palliative care only</i>	54

Answer: Please see table above, representing the latest available data for 1st September 2022 to 30th November 2022.